Showing 141-150 of 325 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Development of Uni-molecular Glucose-responsive Insulin | Stanford University | Danny Hung-Chieh Chou | Improving Lives | 01-April-2022 to 31-March-2026 | $749,998.34 |
| Development of an injectable immunomodulatory niche technology for induction of immune tolerance to islet cell transplants | Stanford University | Eric Appel | Cures | 01-January-2025 to 31-December-2026 | $600,000.00 |
| Ultrafast Insulin-Pramlintide Co-formulations | Stanford University | Eric Appel | Improving Lives | 01-September-2022 to 31-December-2026 | $795,000.00 |
| Endothelial cells for islet replacement in diabetes | Stanford University | Martin Neukam | Cures | 01-April-2024 to 31-March-2027 | $251,600.00 |
| Single-arm intervention trial of TWIIST™ AID DEKA Loop insulin pump in pregnant women with pre-existing type 1 diabetes | Stanford University | Tugce Akcan | Improving Lives | 01-March-2025 to 28-February-2027 | $180,600.00 |
| Novel insulin formulations for pumps | Stanford University | Yanxian Zhang | Improving Lives | 01-March-2023 to 28-February-2026 | $243,986.00 |
| Achieving Health in Emerging Adults with Diabetes Program | Seattle Childrens Hospital | Faisal Malik | Improving Lives | 01-September-2024 to 31-August-2028 | $1,734,029.00 |
| PREdictors for DiabetIC Ketoacidosis at Diagnosis of Type 1 Diabetes (The PREDICT study) | Rutgers, The State University of New Jersey | Chintan Dave | Cures | 01-August-2022 to 31-July-2025 | $695,404.04 |
| The master regulator transcription factor, Zbtb20, defines and controls a regulatory T cell subset that controls tissue inflammation. | Rutgers Biomedical and Health Sciences | Derek Sant’Angelo | Cures | 01-March-2023 to 28-February-2027 | $552,029.35 |
| Treating Type 1 Diabetes: Role of Kisspeptin | Rutgers Biomedical and Health Sciences | Moshmi Bhattacharya | Cures | 01-April-2024 to 31-March-2026 | $140,000.00 |